In an ITT analysis, all randomized patients are in cluded in the analysis in their assigned groups regardless of all considerations, including whether they in fact received the designated intervention. ITT analys is should therefore compare outcomes in groups that correspond exactly to the randomization scheme. Any deviation from that principle may introduce bias.
An immediate problem is that some data are missing from almost all randomized trials. 3 Clearly, just a few missing outcomes will not be a concern, but one review found that, in about half of randomized controlled trials (RCTs), outcomes are missing for more than 10% of par ticipants. 4 A major concern is that being lost to follow up could be related to a patient's response to the treat ment; indeed, we should assume that this will be so. That concern can be compounded if the reasons for, or frequency of, dropout differs between the treatment groups.
No analysis option is ideal here; there is, in effect, a choice between omitting participants without final out come data or estimating (imputing) the missing out come data. What should researchers do? A "complete case" (or "available case") analysis simply omits those for whom data are incomplete. This commonly used ap proach loses power, and bias may well be introduced, given that the incompleteness of data will not be ran dom. Further, excluding some patients is not compat ible with the ITT principle. Imputation of the missing data allows the analysis to conform to ITT analysis but requires strong assumptions that may be hard to justi fy. 5, 6 However, some concerns about "making up the data" are misplaced. 7 Methods for the imputation of missing values have been the topic of much methodological and empirical research in recent years. The generally preferred im putation methods are quite complex, 58 and some simple approaches that have been around a long time are much more popular. One of the simplest and most commonly used of these in the analysis of continuous outcomes is "last observation carried forward" (LOCF) analysis, in which missing final values of the outcome variable are replaced by the last known value before the participant was lost to followup. LOCF analysis appeals through its simplicity and ease of application, but there are strong grounds for not using it. Specifically, the method may introduce bias in the results, and this bias can, according to circumstance, be in either direction. 9 Also, because in LOCF analysis no allowance is made for the uncertainty of imputation, the resulting confid ence intervals are too narrow. 10 Even if missing outcomes are random across trial participants, LOCF analysis assumes that the missing final values would be the same as the last recorded val ues. That assumption is often implausible (even as an average), because dropping out is likely to be associated with response to treatment; obvious examples are fail ure to respond to treatment and adverse effects. In practice, missing data are very likely to be related to re sponse to treatment and prognosis.
Molnar and colleagues have discussed these issues in the specific context of trials of dementia therapies. 9, 11 They found that 34 of 57 RCTs used LOCF as the only form of ITT analysis. Not surprisingly, that is a much higher proportion than the 19% observed in a review of trials across various medical specialties published in 4 general medical journals. 4 As Molnar and colleagues note, 11 their study cannot quantify the magnitude of the effect of the use of LOCF analysis on trial results, but it does highlight the high prevalence of conditions for which this method of ana lysis could promote bias in favour of more toxic ther apies and against less toxic alternatives.
Their study focused on a limited number of trials con cerning a single medical condition, but many of the is sues it raises apply to all trials. It is known that most trials include some patients whose outcomes are ulti mately not known, and for which an ITT analysis is not possible without some type of imputation (although au thors commonly mislabel available case analyses as ITT).
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Whichever imputation approach is used, it is desir able to report analyses with and without imputation. Also, it may be valuable to explore different imputation approaches. As Molnar and colleagues suggest, "the onus is on the investigators who publish these trials to disprove the possibility that these analyses have intro duced bias by performing ITT sensitivity analyses … . This is particularly true for those studies demonstrating higher dropout rates in treatment groups." 11 A further important issue is that this information should be included in the report of a trial. The CON SORT (Consolidated Standards for Reporting of Trials) Statement recommends that authors specify the meth ods used for all statistical analyses reported. 14 The state ment's accompanying explanatory paper included various comments on ITT analysis, but there was no spe cific mention of imputation. 15 Noting that omission, Sha piro wrote: "A variety of options are available to handle missing data from participants who drop out of the trial and it is important for readers to know what strategy the investigators adopted. Without such information, the fact that an intenttotreat analysis was carried out is only partially informative." 16 That omission will be remedied in the forthcoming 2009 update of the CON SORT Statement.
Transparency of reporting facilitates reliable apprais al of the quality and relevance of health research. 17 Suc cessful transparency may be judged by whether others are able to reproduce all the methods used. The Interna tional Committee of Medical Journal Editors makes the sensible recommendation to " [d] escribe statistical meth ods with enough detail to enable a knowledgeable read er with access to the original data to verify the reported results" (http://www.icmje.org/). That is very sound ad vice for all research articles, not just RCTs; indeed, I see no reason why it should not apply to all study methods.
Molnar and colleagues have gone further than Sha piro by suggesting that the CONSORT group should give guidance on methods for analysing trials when data are missing. 11 However, because the purpose of the CONSORT group is to give guidance on the reporting of what was done, and not to advise on what is good or bad methodology, such guidance will not come from that source. But, given that so many others have warned about the dangers of LOCF analysis, it seems clear that its use as the sole form of analysis should be discontin ued. 8, 9, 16, 18, 19 Finally, as Liu and colleagues observed, it is import ant in the design and conduct of studies to try to pre vent losses to followup and to try to minimize the bias caused by the inevitable missing data. 20 To that end, they provide helpful guidance for both the conduct and reporting of RCTs where missing outcomes are likely:
• discuss at the planning stage methods and procedures that maximize the chance of retaining patients (e.g., short course of rescue medicine), • continue to collect data post-withdrawal to preserve the ITT population, • document the reasons for missing data, • anticipate and investigate the types of missing data, • pre-specify primary as well as sensitivity statistical analyses, • fully report the extent and pattern of missing data, • support conclusions based on results from the planned analyses with proper sensitivity assessment.
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Adherence to this advice will lead to better design, ana lysis, reporting and interpretation of future trials in all medical specialties.
